Luteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis.

Autor: Singh DK; Special Centre for Molecular Medicine (SCMM), Jawaharlal Nehru University, New Delhi, India.; International Centre for Genetic Engineering and Biotechnology, New Delhi, India.; Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, Texas, United States of America., Tousif S; Special Centre for Molecular Medicine (SCMM), Jawaharlal Nehru University, New Delhi, India., Bhaskar A; International Centre for Genetic Engineering and Biotechnology, New Delhi, India., Devi A; Special Centre for Molecular Medicine (SCMM), Jawaharlal Nehru University, New Delhi, India., Negi K; International Centre for Genetic Engineering and Biotechnology, New Delhi, India., Moitra B; Special Centre for Molecular Medicine (SCMM), Jawaharlal Nehru University, New Delhi, India., Ranganathan A; Special Centre for Molecular Medicine (SCMM), Jawaharlal Nehru University, New Delhi, India.; International Centre for Genetic Engineering and Biotechnology, New Delhi, India., Dwivedi VP; International Centre for Genetic Engineering and Biotechnology, New Delhi, India., Das G; Special Centre for Molecular Medicine (SCMM), Jawaharlal Nehru University, New Delhi, India.
Jazyk: angličtina
Zdroj: PLoS pathogens [PLoS Pathog] 2021 Aug 20; Vol. 17 (8), pp. e1009805. Date of Electronic Publication: 2021 Aug 20 (Print Publication: 2021).
DOI: 10.1371/journal.ppat.1009805
Abstrakt: Tuberculosis (TB) remains a major health problem throughout the world with one third of the population latently infected and ~1.74 million deaths annually. Current therapy consists of multiple antibiotics and a lengthy treatment regimen, which is associated with risk for the generation of drug-resistant Mycobacterium tuberculosis variants. Therefore, alternate host directed strategies that can shorten treatment length and enhance anti-TB immunity during the treatment phase are urgently needed. Here, we show that Luteolin, a plant-derived hepatoprotective immunomodulator, when administered along with isoniazid as potential host directed therapy promotes anti-TB immunity, reduces the length of TB treatment and prevents disease relapse. Luteolin also enhances long-term anti-TB immunity by promoting central memory T cell responses. Furthermore, we found that Luteolin enhances the activities of natural killer and natural killer T cells, both of which exhibit antitubercular attributes. Therefore, the addition of Luteolin to conventional antibiotic therapy may provide a means to avoid the development of drug-resistance and to improve disease outcome.
Competing Interests: The authors have declared that no competing interests exist.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje